Clinical efficacy of PARP inhibitors in breast cancer
- 2 May 2023
- journal article
- review article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 200 (1) , 15-22
Abstract
BRCA1 and BRCA2 are key tumor suppressor genes that are essential for the homologous recombination DNA repair pathway. Loss of function mutations in these genes result in hereditary breast and ovarian cancer syndromes, which comprise approximately 5% of cases. BRCA1/2 mutations are associated with younger age of diagnosis and increased risk of recurrences. The concept of synthetic lethality led to the development of PARP inhibitors which cause cell cytotoxicity via the inhibition of PARP1, a key DNA repair protein, in cells with germline BRCA1/2 mutations. Although still poorly understood, the most well-acknowledged proposed mechanisms of action of PARP1 inhibition include the inhibition of single strand break repair, PARP trapping, and the upregulation of non-homologous end joining. Olaparib and talazoparib are PARP inhibitors that have been approved for the management of HER2-negative breast cancer in patients with germline BRCA1/2 mutations. This review article highlights the clinical efficacy of PARP inhibitors in patients with HER2-negative breast cancer in early and advanced settings.Keywords
This publication has 40 references indexed in Scilit:
- PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated ImmunosuppressionClinical Cancer Research, 2017
- Mutational Landscape and Sensitivity to Immune Checkpoint BlockersClinical Cancer Research, 2016
- Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast CancerClinical Cancer Research, 2016
- Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast CancerNew England Journal of Medicine, 2016
- Profile of veliparib and its potential in the treatment of solid tumorsOncoTargets and Therapy, 2015
- Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and RucaparibMolecular Cancer Therapeutics, 2014
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialThe Lancet, 2010
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation CarriersNew England Journal of Medicine, 2009
- Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature, 2005
- Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymeraseNature, 2005